 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12345678910» |
- | imipenem/relebactam / Merck (MSD)
Journal: Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020. (Pubmed Central) - Mar 25, 2023
Imipenem/relebactam showed high rates of susceptibility in Enterobacterales and P. aeruginosa isolates from different sources of infection as well as depending on patients' location (ICU or non-ICU scenarios).
- imipenem/relebactam / Merck (MSD), Sivextro (tedizolid) / Merck (MSD), Nabriva Therap
In Vitro Susceptibility Testing of Imipenem- Relebactam and Tedizolid Against Australian Mycobacterium Abscessus Isolates (Marriott Marquis Washington, Marquis Ballroom, Salons 3-4 (Level M2)) - Mar 25, 2023 - Abstract #ATS2023ATS_2447;
Tedizolid has a significantly 4-fold lower MIC than the comparator antibiotic, linezolid. Whether this will result in an increase in clinical cure is uncertain.
- | Preclinical, Journal: In-vitro-obtained meropenem-vaborbactam resistance mechanisms among clinical KPC-producing Klebsiella pneumoniae isolates. (Pubmed Central) - Mar 21, 2023
Whether this will result in an increase in clinical cure is uncertain. In contrast to what is observed with KPC-producing mutants exhibiting resistance to CAZ-AVI, mainly corresponding to mutated KPC enzymes, here the MEM-VAB-resistant mutants showed permeability defects combined with increased KPC production, resulting from genomic rearrangement.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Phenotypes, genotypes and breakpoints: an assessment of ?-lactam/?-lactamase inhibitor combinations against OXA-48. (Pubmed Central) - Mar 4, 2023
Data demonstrate that current imipenem/relebactam and ceftazidime/avibactam CLSI breakpoints are appropriate. Data also suggest that higher meropenem/vaborbactam breakpoints relative to meropenem can translate to potentially poor clinical outcomes in patients infected with OXA-48-harbouring isolates.
- || Review, Journal: Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales. (Pubmed Central) - Feb 27, 2023
The efficacy and safety of cefiderocol has been demonstrated in three randomised, prospective, parallel group or controlled clinical studies in patients at risk of being infected by multidrug-resistant or carbapenem-resistant Gram-negative bacteria. This paper reviews the in vitro activity, emergence of resistance, preclinical effectiveness, and clinical experience for cefiderocol, and its role in the management of patients with CRE infections.
- | imipenem/relebactam / Merck (MSD)
Preclinical, Journal: In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018-2020. (Pubmed Central) - Feb 10, 2023
Seven of eight molecularly characterized IMR-resistant P. aeruginosa isolates from 2020 were oprD-deficient.Conclusion. IMR may be a potential treatment option for bloodstream, intra-abdominal and urinary tract infections caused by NME and P. aeruginosa in Western Europe, including infections caused by piperacillin/tazobactam-resistant and meropenem-resistant isolates.
- | Journal: Comparative Activity of Newer β-Lactam/β-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa Isolates from United States Medical Centers (2020-2021). (Pubmed Central) - Feb 5, 2023
Cross-resistance among the newer BL/BLIs varied markedly; ≥72.1% of isolates resistant to one of the three newer BL/BLI approved for P. aeruginosa treatment remained susceptible to at least one of the other two, indicating that all 3 should be tested in the clinical laboratory. These 3 BL/BLI agents represent valuable therapeutic options for P. aeruginosa infection treatment.
- imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Unexpected in vitro antagonism between imipenem/relebactam and aztreonam for a NDM Klebsiella pneumoniae failed at combination treatment with ceftazidime/avibactam plus aztreonam (A / 06) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_5073;
- imipenem/relebactam / Merck (MSD)
Real-world effectiveness of imipenem/relebactam for the treatment of Gram-negative infections (B / 14) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2378;
- Fetroja (cefiderocol) / Shionogi
Combined resistance mechanisms leading to a high level of cefiderocol resistance In NDM-producing E. coli ST167 clinical isolates (B / 06) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2268;
- imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Resistance prevention and resistance development dynamics to imipenem and imipenem/relebactam in carbapenem susceptible high-risk clones of Klebsiella pneumoniae KPC ?-loop-mutants showing ceftazidime/avibactam-resistance (B / 07) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2264;
- Assessing the impact of the most relevant chromosomally-encoded and horizontally-acquired Pseudomonas aeruginosa resistance mechanisms on resistance to cefiderocol, imipenem/relebactam, cefepime/taniborbactam, cefepime/zidebactam and aztreonam/avibactam (B / 06) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2236;
- Changes in minimal inhibitory concentrations of several antibiotics in consecutive isolates of KPC-producing K. pneumoniae from long-term colonised patients (B / 09) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2234;
- imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Simultaneous and divergent evolution of resistance to cephalosporin/?-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections (B / 10) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2217;
- Vabomere (meropenem/vaborbactam) / Melinta Therap
In vitro obtained meropenem/vaborbactam resistance mechanisms among clinical KPC-producing Klebsiella pneumoniae isolates (B / 08) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2208;
- Emergence of carbapenemase-producing Klebsiella pneumoniae clinical isolates with a pan-drug resistant (PDR) phenotype in Argentina (B / 09) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2197;
- Fetroja (cefiderocol) / Shionogi
In vitro study of aztreonam plus several ?-lactam-?-lactamase inhibitors synergy and cefiderocol susceptibility against metallo-?-lactamase-producing Pseudomonas aeruginosa (B / 03) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2185;
- Impact of acquired broad-spectrum (B / 03) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2180;
- imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap
Imipenem/relebactam and meropenem/vaborbactam against Enterobacterales : MIC strips or microdilution for susceptibility testing? (B / 02) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2151;
- Fetroja (cefiderocol) / Shionogi
Insights into cefiderocol susceptibility of clinical multidrug-resistant isolates (B / 04) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2117;
- Extension of MBT STAR Carba assay to an inhibitor approach (B / 04) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2114;
- Emergence of carbapenamase-associated atypical clone in Klebsiella pneumoniae isolates during pandemic period in a tertiary hospital in Madrid, Spain (A / 16) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2097;
- Fetroja (cefiderocol) / Shionogi
Cefiderocol in vitro activity against molecularly characterized Acinetobacter baumannii - calcoaceticus complex and Pseudomonas aeruginosa clinical isolates causing infection in Europe and adjacent regions (2020-2021) (A / 16) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2093;
- tetracycline / Generic mfg.
Assessment of activity and resistance mechanisms to novel tetracyclines against a multi-centre collection of carbapenemase-producing Enterobacterales (A / 16) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2079;
- Fetroja (cefiderocol) / Shionogi
In vitro activity of cefiderocol against Pseudomonas aeruginosa isolated from cystic fibrosis patients (A / 15) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2075;
- Fetroja (cefiderocol) / Shionogi
Activity of cefiderocol and comparator agents against US isolates of Pseudomonas aeruginosa , Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia , including carbapenem-resistant isolates from the SENTRY Antimicrobial Surveillance Program (2020 (A / 15) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2065;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
The activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and P. aeruginosa collected in central-north Europe (Belgium, Norway, Sweden, Switzerland): SMART 2017-2021 (A / 15) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2061;
- Fetroja (cefiderocol) / Shionogi
Comparison of in vitro activity of cefiderocol and comparator agents against molecularly characterised carbapenem-resistant Enterobacterales clinical isolates causing infections in Europe and surrounding regions (2020 (A / 13) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2028;
- Identification of KPC-2 and inhibitor-resistant VEB-25 co-produced in a Klebsiella pneumoniae isolate in Switzerland (A / 13) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2021;
- Emergence of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase (A / 13) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2019;
- Fetroja (cefiderocol) / Shionogi
Activity of cefiderocol and comparator agents against European isolates of Pseudomonas aeruginosa , Acinetobacter baumannii-calcoaceticus species complex, and S tenotrophomonas maltophilia from the SENTRY Antimicrobial Surveillance Programme (2020 (A / 12) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2005;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical Gram-negative isolates collected in Mexico from patients with lower respiratory tract infections (A / 11) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1987;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and P. aeruginosa collected in Greece and Italy: SMART 2017-2021 (A / 11) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1982;
- imipenem/relebactam / Merck (MSD)
In vitro (A / 11) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1980;
- imipenem/relebactam / Merck (MSD)
Activity of imipenem/relebactam against Gram-negative pathogens from paediatric patients in Asia/Pacific (A / 10) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1966;
- Fetroja (cefiderocol) / Shionogi
Activity of cefiderocol against carbapenemase-producing Enterobacterales (CPE) in the post COVID-19 era: results of a prospective, multicenter study in Argentina (A / 10) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1965;
- imipenem/relebactam / Merck (MSD)
Global analysis of the in vitro activity of imipenem/relebactam against KPC-encoding Enterobacterales 2018-2021 (A / 09) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1951;
- Fetroja (cefiderocol) / Shionogi, Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
In vitro activity of cefiderocol, eravacycline and ?-lactam-?-lactamase inhibitor combinations against carbapenemase-producing Enterobacterales isolated in western Normandy, France, during a 5 years period (A / 09) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1947;
- Fetroja (cefiderocol) / Shionogi
Susceptibility of phenotypic subsets of Pseudomonas aeruginosa isolates of cefiderocol and comparator agents from SENTRY 2020-2021 (A / 08) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1932;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative pathogens before and during the COVID-19 pandemic: SMART United States 2018-2021 (A / 06) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1898;
- Fetroja (cefiderocol) / Shionogi
Activity of cefiderocol and comparator agents against US Enterobacterales, including carbapenem-resistant isolates from the SENTRY Antimicrobial Surveillance Programme (2020 (A / 06) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1893;
- Fetroja (cefiderocol) / Shionogi
Activity of cefiderocol and comparator agents against European Enterobacterales, including carbapenem-resistant isolates, grom the SENTRY Antimicrobial Surveillance Program (2020 (A / 04) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1858;
- Enterobacterales co-harbouring two carbapenemases in a tertiary hospital in Madrid, Spain: a new epidemiological scenario? (Hall B) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1287;
- imipenem/relebactam / Merck (MSD)
Activity of imipenem/relebactam and comparators against clinical MDR and DTR Pseudomonas aeruginosa isolates: SMART, United States, 2019-2021 (Arena 1) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_763;
- | Zemdri (plazomicin) / Ionis, Achaogen
Preclinical, Journal: In vitro activity of newer β-lactam/β-lactamase inhibitor combinations, cefiderocol, plazomicin and comparators against carbapenemase-producing Klebsiella pneumoniae isolates. (Pubmed Central) - Jan 28, 2023
All KPC-producing K. pneumoniae were susceptible to ceftazidime-avibactam (CAZ/AVI) and meropenem-vaborbactam (M/V) and 97.2% of them to imipenem-relebactam (I/R). Among the MBL-producing isolates, PL and CFDC exhibited the highest activity.
- | imipenem/relebactam / Merck (MSD)
Preclinical, Journal: In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with lower respiratory tract infections in Western Europe: SMART 2018-20. (Pubmed Central) - Jan 26, 2023
Among molecularly characterized imipenem/relebactam-resistant P. aeruginosa isolates from 2020, 90.9% (30/33) were oprD deficient. Imipenem/relebactam appears to be a potential treatment option for lower respiratory tract infections caused by piperacillin/tazobactam- and meropenem-resistant NME and P. aeruginosa in Western Europe.
- || PK/PD data, Journal, Gram negative: Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams. (Pubmed Central) - Jan 20, 2023
Optimizing antimicrobial therapy with novel beta-lactams based on the so called "antimicrobial therapy puzzle" PK/PD concepts may represent a definitive jump into the future toward a personalized patient management of DTR Gram negative infections. Establishing a dedicated and coordinated multidisciplinary team and implementing a real-time TDM-guided personalized antimicrobial exposure optimization of novel beta-lactams based on expert clinical pharmacological interpretation, could represent crucial cornerstones for the proper management of DTR Gram-negative infections.
- imipenem/relebactam / Merck (MSD), Recarbrio (relebactam/imepenem/cilastatin) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Observational data, Journal, Gram negative: Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: A real-life study. (Pubmed Central) - Dec 23, 2022
However, data regarding the use of imipenem-cilastatin-relebactam (IMI-REL), cefiderocol (CFD) and ceftazidime-avibactam plus aztreonam (CAZ-AVI-ATM) are scarce in real-life settings...After a treatment course with CFD, CAZ-AVI-ATM and IMI-REL, the probability of infection-free survival was 48% CI95% [10.4-73.5], 33.3% CI95% [6.7-100], 66.7% CI95% [30-100], respectively. Use of last resort beta-lactam antimicrobials in real-life settings was a safe and efficient therapeutic option for severe infections related to Gram-negative bacteria with Difficult-to-Treat Resistance.
- | Journal, Gram negative: New antibiotics for Gram-negative pneumonia. (Pubmed Central) - Dec 22, 2022
Several novel antibiotics have potent activity against multidrug-resistant Pseudomonas aeruginosa, such as ceftazidime-avibactam, ceftolozane-tazobactam, imipenem-relabactam and cefiderocol. Cefiderocol may also play an important role in the management of pneumonia caused by Acinetobacter baumannii, along with plazomicin and eravacycline.
- || PK/PD data, Review, Journal: Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation. (Pubmed Central) - Dec 12, 2022
Critically ill patients presenting with special circumstances might be at risk of altered NBLA pharmacokinetics, particularly in the settings of ARC and RRT. More robust, well-designed trials are still required to define effective dose regimens able to attain therapeutic PK/PD indices of NBLA when utilized in those special scenarios, and thus aid in improving the patients' outcomes.